Table 3.
Cytotoxicity (IC50) of B16 melanoma and HeLa cervical carcinoma cells.
| Compound | Cytotoxicity IC50 (μM) a | |
|---|---|---|
| B16 | HeLa | |
| 5 | 14.6 ± 0.5 | 17.4 ± 2.0 |
| 6 | 13.9 ± 1.1 | 15.9 ± 3.3 |
| 7 | 20.9 ± 1.8 | 18.1 ± 0.7 |
| 8 | 18.5 ± 0.6 | 20.3 ± 3.5 |
| 13 | 17.0 ± 1.4 | 16.4 ± 1.9 |
| 14 | 13.1 ± 1.2 | 17.5 ± 1.4 |
| 15 | 27.9 ± 1.6 | 21.5 ± 0.9 |
| 16 | 28.6 ± 1.0 | 20.5 ± 1.4 |
| BPA | 44.9 ± 0.3 | n.d. b |
a B16 melanoma and HeLa cervical cancer cells were incubated for 72 h in the presence of compounds 5–8 and 13–16, and then the percentages of viable cells were determined by MTT assay. The drug concentrations required to inhibit cell viability by 50% (IC50) were determined from semi-logarithmic concentration-response plots, and the results represent the means ± s.d. of triplicate samples. b n.d., not determined.